Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 肥厚性心肌病 安慰剂 内科学 心脏病学 临床终点 心肌病 心室流出道 心力衰竭 随机对照试验 病理 替代医学
作者
Iacopo Olivotto,Artur Oręziak,Roberto Barriales‐Villa,Theodore P. Abraham,Ahmad Masri,Pablo García‐Pavía,Sara Saberi,Neal K. Lakdawala,Matthew T. Wheeler,Anjali Owens,Miloš Kubánek,Wojciech Wojakowski,Juan R. Gimeno,K. Afshar,Jonathan Myers,Sheila M. Hegde,Scott D. Solomon,Amy J. Sehnert,David Zhang,Wanying Li,Mondira Bhattacharya,Jay M. Edelberg,Cynthia Burstein Waldman,Andrew Wang,Andrew Wang,Carolyn Y. Ho,Daniel Jacoby,Jozef Bartúnek,Antoine Bondue,Emeline M. Van Craenenbroeck,David Zemánek,Morten K. Jensen,Jens Mogensen,Jens Jakob Thune,Philippe Charron,Antoine Lafont,Olivier Lairez,Jean‐Noël Trochu,Christoph Axthelm,Hans‐Dirk Duengen,Norbert Frey,Veselin Mitrović,Michael Preusch,Jeanette Schulz‐Menger,Tim Seidler,Michael Arad,Majdi Halabi,Amos Katz,Daniel Monakier,Offir Paz,Samuel Viskin,Donna R. Zwas,Hans‐Peter Brunner‐La Rocca,Michelle Michels,Dariusz Dudek,Zofia Oko‐Sarnowska,Nuno Cardim,Hélder Pereira,Pablo García Pavía,Juan Gimeno Blanes,Rafael Hidalgo Urbano,Luis Alonso-Pulpón,Perry Elliott,Zaheer Yousef,Paulino Alvarez,Richard G. Bach,Richard C. Becker,Lubna Choudhury,David Fermin,John L. Jefferies,Christopher M. Kramer,Ali J. Marian,Matthew J. Maurer,Sherif F. Nagueh,David S. Owens,Florian Rader,Mark V. Sherrid,Jamshid Shirani,John D. Symanski,Aslan T. Turer,Omar Wever‐Pinzon,Timothy C. Wong,Mohamad H. Yamani
出处
期刊:The Lancet [Elsevier]
卷期号:396 (10253): 759-769 被引量:642
标识
DOI:10.1016/s0140-6736(20)31792-x
摘要

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy. Methods In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II–III symptoms were assigned (1:1) to receive mavacamten (starting at 5 mg) or placebo for 30 weeks. Visits for assessment of patient status occurred every 2–4 weeks. Serial evaluations included echocardiogram, electrocardiogram, and blood collection for laboratory tests and mavacamten plasma concentration. The primary endpoint was a 1·5 mL/kg per min or greater increase in peak oxygen consumption (pVO2) and at least one NYHA class reduction or a 3·0 mL/kg per min or greater pVO2 increase without NYHA class worsening. Secondary endpoints assessed changes in post-exercise LVOT gradient, pVO2, NYHA class, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore (HCMSQ-SoB). This study is registered with ClinicalTrials.gov, NCT03470545. Findings Between May 30, 2018, and July 12, 2019, 429 adults were assessed for eligibility, of whom 251 (59%) were enrolled and randomly assigned to mavacamten (n=123 [49%]) or placebo (n=128 [51%]). 45 (37%) of 123 patients on mavacamten versus 22 (17%) of 128 on placebo met the primary endpoint (difference +19·4%, 95% CI 8·7 to 30·1; p=0·0005). Patients on mavacamten had greater reductions than those on placebo in post-exercise LVOT gradient (−36 mm Hg, 95% CI −43·2 to −28·1; p<0·0001), greater increase in pVO2 (+1·4 mL/kg per min, 0·6 to 2·1; p=0·0006), and improved symptom scores (KCCQ-CSS +9·1, 5·5 to 12·7; HCMSQ-SoB −1·8, −2·4 to −1·2; p<0·0001). 34% more patients in the mavacamten group improved by at least one NYHA class (80 of 123 patients in the mavacamten group vs 40 of 128 patients in the placebo group; 95% CI 22·2 to 45·4; p<0·0001). Safety and tolerability were similar to placebo. Treatment-emergent adverse events were generally mild. One patient died by sudden death in the placebo group. Interpretation Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. The results of this pivotal trial highlight the benefits of disease-specific treatment for this condition. Funding MyoKardia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
PeterParker发布了新的文献求助10
1秒前
脑洞疼应助LJJZZX采纳,获得10
1秒前
礼拜天完成签到,获得积分10
3秒前
小鱼完成签到,获得积分10
4秒前
橘子完成签到,获得积分10
4秒前
1257应助王旭东采纳,获得10
5秒前
6秒前
hhh应助小徐医生采纳,获得10
7秒前
粗暴的小熊猫完成签到 ,获得积分10
9秒前
万能图书馆应助寻雪采纳,获得10
10秒前
完美世界应助yuan采纳,获得10
10秒前
10秒前
hhhhh完成签到,获得积分10
12秒前
QP34完成签到 ,获得积分10
14秒前
尼莫完成签到,获得积分10
14秒前
14秒前
曾婉娟发布了新的文献求助10
15秒前
薰硝壤应助霖槿采纳,获得30
15秒前
曹文鹏发布了新的文献求助10
17秒前
薰硝壤应助单纯的雅香采纳,获得10
18秒前
20秒前
20秒前
22秒前
euphoria发布了新的文献求助10
22秒前
大模型应助叮咚采纳,获得10
23秒前
23秒前
852应助Apple采纳,获得10
24秒前
爆米花应助科研通管家采纳,获得10
24秒前
cctv18应助科研通管家采纳,获得10
25秒前
Orange应助科研通管家采纳,获得10
25秒前
25秒前
神勇秋白完成签到,获得积分0
25秒前
英姑应助科研通管家采纳,获得10
25秒前
曦子曦子应助科研通管家采纳,获得10
25秒前
顾矜应助科研通管家采纳,获得10
25秒前
25秒前
华仔应助科研通管家采纳,获得30
26秒前
26秒前
852发布了新的文献求助10
26秒前
曦子曦子应助科研通管家采纳,获得10
26秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3061106
求助须知:如何正确求助?哪些是违规求助? 2716483
关于积分的说明 7450016
捐赠科研通 2362416
什么是DOI,文献DOI怎么找? 1252135
科研通“疑难数据库(出版商)”最低求助积分说明 607939
版权声明 596536